Maiy.Ns
MAIY.NS operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment, and generates revenue primarily through its operations in this sector.
Business. MAIY.NS operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment, and generates revenue primarily through its operations in this sector.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MAIY.NS operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment, and generates revenue primarily through its operations in this sector.
The company maintains a relatively strong liquidity position, with a current ratio of 2.58, indicating that it has more than twice the current assets to cover its current liabilities. However, the liquidity risk is rated as medium, and the company has a negative net cash position after subtracting total debt, which could pose a challenge in the short term.
In terms of profitability, the company's return on equity (ROE) is 5.84%, and its return on assets (ROA) is 3.9%. These figures are below the typical thresholds for strong performance in the healthcare sector, suggesting that the company is not generating returns as efficiently as its peers.
The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no significant geographic diversification mentioned. This concentration could expose the company to higher risk if the segment or region experiences a downturn.
Looking at the growth trajectory, the company's capital expenditures are negative at -23.81 million INR, indicating that it is not investing in new assets. This could signal a lack of growth initiatives or a focus on cost reduction, which may affect its long-term competitiveness.
The company's risk profile includes a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, and the company has not made any adjustments to its valuation metrics that would suggest a need for dilution.
Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company's financials remain stable, with no significant events reported in the latest filings.
- The company has a strong current ratio but faces medium liquidity risk due to a negative net cash position.
- Return on equity and return on assets are below typical thresholds for the healthcare sector.
- Revenue is concentrated in a single segment, increasing exposure to sector-specific risks.
- Capital expenditures are negative, suggesting a lack of investment in growth.
- The company has a low dilution risk and no significant adjustments to its valuation metrics.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- MAIY.NS Market data — financials · 2026-05-28